Amyotrophic Lateral Sclerosis News and Research

RSS

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

In just 21 days, CVS/pharmacy's ninth annual in-store fundraising campaign to support the fight against amyotrophic lateral sclerosis (ALS) brought in $4.1 million. The funds raised by the campaign will be donated to the Boston-based ALS Therapy Alliance (ATA) to support the funding of new clinical research aimed at developing new therapies for ALS patients and focused on the ultimate goal of finding a cure for ALS.

1 Oct 2010

USFDA approves Sun Pharmaceutical's ANDA to market Rilutek tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.

29 Sep 2010

AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website

AVANIR Pharmaceuticals, Inc. today announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).

15 Sep 2010

Metabolon receives patent for metabolic age analysis

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,781,160 entitled "Biomarkers Related to Metabolic Age and Methods Using the Same". The USPTO awarded the patent to Metabolon on August 24, 2010. This is the 12th patent issued to Metabolon.

14 Sep 2010

Special journal issue highlights obsessive compulsive disorder and Tourette's disorder therapies

Pediatric onset obsessive compulsive disorder (OCD) and Tourette's disorder (TD) share similarities in their underlying genetic and environmental factors, psychiatric features, and treatment methods. Advances in understanding the neurobiological basis of these disorders and discovering new and more effective therapies are highlighted in a special issue on OCD and TD in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

10 Sep 2010

Research on motor neuron subtype may provide useful therapy for neuron diseases

Scientists have devised a method for coaxing mouse embryonic stem cells into forming a highly specific motor neuron subtype. The research, published by Cell Press in the September 3rd issue of the journal Cell Stem Cell, provides new insight into motor neuron differentiation and may prove useful for devising and testing future therapies for motor neuron diseases.

3 Sep 2010

Critical mechanistic link between mutant protein and disease pathogenesis in ALS uncovered

New research uncovers what may be a primary neuron-damaging insult that occurs in an inherited form of a devastating neurodegenerative disorder. The study, published by Cell Press in the August 26th issue of the journal Neuron, describes a critical mechanistic link between a mutant protein and disease pathogenesis in an animal model of amyotrophic lateral sclerosis (ALS).

26 Aug 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

An international study led by biologists and neuroscientists from the University of Pennsylvania has identified a new genetic risk factor for amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig's disease.

26 Aug 2010

Study finds genetic change in chromosome 4 causes FSHD

The Muscular Dystrophy Association today heralds a landmark muscular dystrophy advance by an international study team of scientists and physicians from the Netherlands, United States, France and Spain. Led by MDA-grantee Silvère van der Maarel, Ph.D., at Leiden University Medical Center in the Netherlands, the collaborative study of more than 2,300 people found that two distinct genetic changes on chromosome 4 must be present to cause facioscapulohumeral muscular dystrophy (FSHD).

21 Aug 2010

First pathological evidence of link between repeated head injuries and chronic traumatic Encephalomyopathy

Researchers with the Department of Veterans Affairs (VA) and the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine have provided the first pathological evidence of a link between repeated head injuries—such as those experienced by athletes in contact sports such as boxing, football, and hockey—and a disease (chronic traumatic Encephalomyopathy) that resembles amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

20 Aug 2010

Muscular Dystrophy Association awards $14.1M in new grants

The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants.

20 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

18 Aug 2010

Brain trauma in sports associated with motor neuron disease, researchers find

The Center for the Study of Traumatic Encephalopathy at Boston University School of Medicine and Department of Veterans Affairs announced today that they have provided the first pathological evidence that repetitive head trauma experienced in collision sports is associated with motor neuron disease, a neurological condition that affects voluntary muscle movements.

18 Aug 2010

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

Professional athletes with repetitive head trauma and possibly others with a history of head injuries many years previously may be prone the development of a motor neuron disease similar to amyotrophic lateral sclerosis (ALS or "Lou Gehrig's disease"), reports a study in the September Journal of Neuropathology & Experimental Neurology, official journal of the American Association of Neuropathologists, Inc.

18 Aug 2010

NACTN receives grant to expand spinal cord injury research

The United States Department of Defense (DoD) awarded the Christopher & Dana Reeve Foundation a $5.4 million grant to support the expansion of translational research to find treatments for military men and women with spinal cord injuries.

18 Aug 2010

CVS/Pharmacy opens new store in Omaha

CVS/pharmacy celebrated its entry into the Omaha market today with a grand opening at one of its two new stores in the city of Omaha. Joining CVS officials at the ceremony were The Honorable Jim Suttle, Mayor of Omaha and City Councilmember Thomas Mulligan, District #7.

16 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Amyotrophic Lateral Sclerosis News and Research

Neuraltus achieves last patient out for NP001, NP002 studies

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

USFDA approves Sun Pharmaceutical's ANDA to market Rilutek tablets

AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website

Metabolon receives patent for metabolic age analysis

Special journal issue highlights obsessive compulsive disorder and Tourette's disorder therapies

Research on motor neuron subtype may provide useful therapy for neuron diseases

Critical mechanistic link between mutant protein and disease pathogenesis in ALS uncovered

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

Study finds genetic change in chromosome 4 causes FSHD

First pathological evidence of link between repeated head injuries and chronic traumatic Encephalomyopathy

Muscular Dystrophy Association awards $14.1M in new grants

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Brain trauma in sports associated with motor neuron disease, researchers find

Specific brain abnormalities linked to motor neuron disease in athletes with head trauma

NACTN receives grant to expand spinal cord injury research

CVS/Pharmacy opens new store in Omaha

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News